VIPIDIA Film-coated Tablet
Alogliptin (as benzoate)
25 mg
The Arab Pharmaceutical Manufacturing PSC
| Pack size | 28's Pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 3.78 AED |
Available as:
Indications
VIPIDIA Film-coated Tablet is used for:
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Alogliptin (as benzoate) :
Mechanism of Action
Alogliptin inhibits dipeptidyl peptidase 4 (DPP-4), which normally degrades the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 ( GLP-1). The inhibition of DPP-4 increases the amount of active plasma incretins which helps with glycemic control. GIP and GLP-1 stimulate glucose dependent secretion of insulin in pancreatic beta cells. GLP-1 has the additional effects of suppressing glucose dependent glucagon secretion, inducing satiety, reducing food intake, and reducing gastric emptying.
Note
VIPIDIA 25 mg Film-coated Tablet manufactured by The Arab Pharmaceutical Manufacturing PSC. Its generic name is Alogliptin (as benzoate). VIPIDIA is availble in Saudi Arabia.
Farmaco SA drug index information on VIPIDIA Film-coated Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.